{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:07Z","timestamp":1786735747730,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Indian Soc Pedod Prev Dent"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/1319-2442.261333","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T07:13:01Z","timestamp":1561533181000},"page":"198","source":"Crossref","is-referenced-by-count":9,"title":["A histopathological comparison of pulpal response to formocresol and sodium hypochlorite used as pulpotomy medicaments: In primary teeth \u2013 A clinical trialA histopathological comparison of pulpal response to formocresol and sodium hypochlorite used as pulpotomy medicaments: In primary teeth \u2013 A clinical trial"],"prefix":"10.4103","volume":"37","author":[{"given":"SrikanthReddy","family":"Kola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NVenugopal","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sneha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAjay","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Niharika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PJayachandra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1319-2442.261333-1","first-page":"2715","volume-title":"Prevalence and clinical impact of cytomegalo-virus infection and disease in renal transplantation: Ten years of experience in a single center","author":"Giakoustidis","year":"2012","journal-title":"Transplant Proc"},{"key":"key-10.4103\/1319-2442.261333-2","first-page":"623","volume-title":"Antiviral treatment of cytomegalovirus infection: An update","author":"H\u00e4rter","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/1319-2442.261333-3","first-page":"191","volume-title":"Antiviral treatment of cytomegalovirus infection and resistant strains","author":"Schreiber","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/1319-2442.261333-4","first-page":"419","volume-title":"Emerging cytomegalovirus management strategies after solid organ transplantation: Challenges and opportunities","author":"Beam","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"key-10.4103\/1319-2442.261333-5","first-page":"1075","volume-title":"Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"key-10.4103\/1319-2442.261333-6","first-page":"3930","volume-title":"The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection","author":"Clippinger","year":"2011","journal-title":"J Virol"},{"key":"key-10.4103\/1319-2442.261333-7","first-page":"875","volume-title":"Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation","author":"San","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/1319-2442.261333-8","first-page":"397","volume-title":"Immunosuppressive therapy and infection after kidney transplantation","author":"Fortun","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"key-10.4103\/1319-2442.261333-9","first-page":"175","volume-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial","author":"Guba","year":"2010","journal-title":"Transplantation"},{"key":"key-10.4103\/1319-2442.261333-10","first-page":"2035","volume-title":"Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: A systematic review and meta-analysis","author":"Su","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"key-10.4103\/1319-2442.261333-11","first-page":"2655","volume-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"key-10.4103\/1319-2442.261333-12","doi-asserted-by":"crossref","unstructured":"Van Gurp E, Bustamante J, Franco A, et al. Comparable renal function at 6 months with tacrolimus combined with fixed-dose sirolimus or MMF: Results of a randomized multicenter trial in renal transplantation. J Transplant 2010;2010. pii: 731426.","DOI":"10.1155\/2010\/731426"},{"key":"key-10.4103\/1319-2442.261333-13","first-page":"2453","volume-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials","author":"Brennan","year":"2011","journal-title":"Am J Transplant"},{"key":"key-10.4103\/1319-2442.261333-14","first-page":"1170","volume-title":"Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: A systematic review and meta-analysis","author":"Almeida","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"key-10.4103\/1319-2442.261333-15","first-page":"2522","volume-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycopheno-late mofetil and a 6-month course of steroids","author":"B\u00fcchler","year":"2007","journal-title":"Am J Transplant"},{"key":"key-10.4103\/1319-2442.261333-16","first-page":"1234","volume-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"key-10.4103\/1319-2442.261333-17","first-page":"103","volume-title":"Decreased cytomegalo-virus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients","author":"Ozaki","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"key-10.4103\/1319-2442.261333-18","first-page":"466","volume-title":"Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients","author":"Haririan","year":"2007","journal-title":"Clin Transplant"},{"key":"key-10.4103\/1319-2442.261333-19","first-page":"675","volume-title":"The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients","author":"Ozaki","year":"2007","journal-title":"Clin Transplant"},{"key":"key-10.4103\/1319-2442.261333-20","first-page":"2457","volume-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","author":"Atabani","year":"2012","journal-title":"Am J Transplant"},{"key":"key-10.4103\/1319-2442.261333-21","unstructured":"Fryer JF, Heath AB, Anderson R, Minor PD; Collaborative Study Group, editor. Expert Committee on Biological Standardization: Collaborative Study to Evaluate the Proposed 1st World Health Organization (WHO) International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)-Based Assays. World Health Organization; 2010."},{"key":"key-10.4103\/1319-2442.261333-22","first-page":"1115","volume-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant"},{"key":"key-10.4103\/1319-2442.261333-23","first-page":"119","volume-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: The randomized ZEUS study","author":"Budde","year":"2015","journal-title":"Am J Transplant"},{"key":"key-10.4103\/1319-2442.261333-24","first-page":"416","volume-title":"Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: Observational results at 24 and 36 months after transplantation","author":"Guba","year":"2012","journal-title":"Transpl Int"},{"key":"key-10.4103\/1319-2442.261333-25","first-page":"2562","volume-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.261333-26","first-page":"1013","volume-title":"Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment","author":"Stern","year":"2014","journal-title":"Transplantation"},{"key":"key-10.4103\/1319-2442.261333-27","first-page":"574","volume-title":"Universal valganciclovir prophylaxis significantly reduces episodes of first-year cytomegalovirus disease and biopsy-proven acute rejection in kidney transplant recipients","author":"Tu","year":"2014","journal-title":"Transplant Proc"},{"key":"key-10.4103\/1319-2442.261333-28","first-page":"210","volume-title":"Ganciclovir-resistant cytomegalovirus infection in renal transplantation","author":"Vaz","year":"2014","journal-title":"Clin Kidney J"},{"key":"key-10.4103\/1319-2442.261333-29","first-page":"e78","volume-title":"Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors","author":"Sab\u00e9","year":"2012","journal-title":"Transpl Int"},{"key":"key-10.4103\/1319-2442.261333-30","first-page":"199","volume-title":"Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient","author":"Imamura","year":"2012","journal-title":"Int Heart J"}],"container-title":["Journal of Indian Society of Pedodontics and Preventive Dentistry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:33:10Z","timestamp":1786732390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1319-2442.261333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"alternative-id":["261333"],"URL":"https:\/\/doi.org\/10.4103\/1319-2442.261333","relation":{},"ISSN":["0970-4388"],"issn-type":[{"value":"0970-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}